NMDA receptor antagonists mitigate COVID-19-induced neuroinflammation and improve survival in a mouse model
Антагонисты рецепторов NMDA ослабляют нейровоспаление, вызванное COVID-19, и повышают выживаемость в модели на мышах
2025-06-04
SCID: 54.1/cdy9hgat
Discuss with AI
COVID-19 neuroinflammationMemantineMouse modelNMDA receptor antagonistsSARS-CoV-2
Figures from the paper
Abstract (AI)
The virus known to cause COVID-19, SARS-CoV-2, exhibits severe and complex neurological symptoms. These effects may be attributed to a virus-induced neuroinflammatory environment, warranting exploration of the respiratory centers of the brain, namely the pons and medulla, specifically in relation to neuroinflammation, demyelination, and neuronal death in response to COVID-19. Interestingly, older adults with neurological dysfunction maintained on N-methyl-D-aspartate receptor (NMDAR) antagonists, such as memantine, had reduced incidence and severity of COVID-19. Thus, the present study aimed to evaluate (1) the neuroinflammatory response to COVID-19 in the respiratory centers of the brain, and (2) to assess the extent to which NMDAR antagonists offer neuroprotective measures in the context of COVID-19. In a susceptible mouse model, animals inoculated with SARS-CoV-2 were pre-treated with either memantine or an alternative NMDAR antagonist, ifenprodil. Inoculated animals had poor survival and showed signs of neuroinflammation, evidenced by a reduction in morphological structure, demyelination, and changes in astrocyte and microglial expression in the pons and medulla. Mice pre-treated with memantine showed improved survival when challenged with COVID-19 and a reduction in virus-induced neuroinflammatory impairments. Our findings support the further investigation of memantine for the prevention of COVID-19 induced neuroinflammation and resultant neurological symptoms and shed light on the possible protective mechanism of memantine in the elderly maintained on NMDAR antagonists.
Key Findings
1
COVID-19-related brainstem pathology included reduced morphological integrity, demyelination, and altered astrocyte and microglial expression.
2
Pre-treatment with memantine improved survival in SARS-CoV-2-challenged mice and reduced virus-induced neuroinflammatory impairments.
3
SARS-CoV-2 infection in susceptible mice caused poor survival and neuroinflammatory damage in the pons and medulla.
4
The findings support further investigation of memantine as a preventive treatment for COVID-19-associated neuroinflammation and neurological symptoms.
5
The study suggests a potential protective role of NMDAR antagonism in older adults receiving such medications.
Research Object
SARS-CoV-2 infection in the pons and medulla of a susceptible mouse model
Research Subject
COVID-19-induced neuroinflammation, demyelination, neuronal damage, and survival, and their mitigation by NMDAR antagonists
Publication Details
Publication Date
2025-06-04
Journal
Publisher
ISSN
Cited by
3
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai6
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China2020
The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients2020
Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-192020
The semantics of microglia activation: neuroinflammation, homeostasis, and stress2021
Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology2020
Neurological complications and infection mechanism of SARS-CoV-22021